aTyr Pharma (ATYR) catalysts

Upcoming FDA decisions and readouts we track for aTyr Pharma, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for aTyr Pharma (ATYR, listed on Nasdaq). It concerns Efzofitimod (Systemic sclerosis-associated interstitial lung disease).

First on the list: the Phase 2 readout for Efzofitimod (Systemic sclerosis-associated interstitial lung disease), guided by the company to Q1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: ATYR
Next catalyst: Q1 2027
Type: Phase 2 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
aTyr Pharma ATYR · Nasdaq	Efzofitimod	Systemic sclerosis-associated interstitial lung disease	Q1 2027 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Topline results are expected in the first quarter of 2027." Source: 8-K exhibit 99.1, filed 07 Aug 2026 · verified 11 Sep 2026

Companies working on related conditions

Roivant Sciences (ROIV)Non-infectious uveitis; Cutaneous lupus erythematosus; Pulmonary hypertension with interstitial lung disease; Difficult-to-treat rheumatoid arthritis; Graves’ d
Zura Bio (ZURA)Hidradenitis suppurativa; Systemic sclerosis

Also due in Q1 2027

Aktis Oncology (AKTS)Phase 1B readout for AKY-1189, Q1 2027
Apnimed (APMD)PDUFA date for AD109 (Oxnimbi), 28 Feb 2027
Cullinan Therapeutics (CGEM)PDUFA date for Zipalertinib, 27 Feb 2027
ImmunityBio (IBRX)PDUFA date for ANKTIVA (nogapendekin alfa) plus BCG, 06 Jan 2027
Annovis Bio (ANVS)Phase 3 readout for Buntanetap, Q1 2027
Intellia Therapeutics (NTLA)PDUFA date for Lonvoguran ziclumeran (lonvo-z), 10 Mar 2027